Cargando…

The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells

AIMS: To understand the mechanism by which imeglimin (a new oral hypoglycemic agent whose phase 3 development program in Japan has now been completed) decreases hepatic glucose production. MATERIALS AND METHODS: We compared the effect of imeglimin and metformin on glucose production, ATP/ADP ratio,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vial, Guillaume, Lamarche, Frédéric, Cottet‐Rousselle, Cécile, Hallakou‐Bozec, Sophie, Borel, Anne‐Laure, Fontaine, Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8029524/ https://www.ncbi.nlm.nih.gov/pubmed/33855213 http://dx.doi.org/10.1002/edm2.211

Ejemplares similares

Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes
por: Hallakou‐Bozec, Sophie, et al.
Publicado: (2020)

Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration
por: Detaille, D, et al.
Publicado: (2016)

Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin
por: Theurey, Pierre, et al.
Publicado: (2022)

Imeglimin preserves islet β‐cell mass in Type 2 diabetic ZDF rats
por: Hallakou‐Bozec, Sophie, et al.
Publicado: (2020)

Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action
por: Hallakou-Bozec, Sophie, et al.
Publicado: (2021)

Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity
por: Theurey, Pierre, et al.
Publicado: (2022)

Liver mitochondrial function in ZDF rats during the early stages of diabetes disease
por: Vial, Guillaume, et al.
Publicado: (2016)

Short‐and long‐term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndrome
por: Lachaux, Marianne, et al.
Publicado: (2020)

Molecular Mechanisms by Which Imeglimin Improves Glucose Homeostasis
por: Yaribeygi, Habib, et al.
Publicado: (2020)

Human mesenchymal stem cells improve rat islet functionality under cytokine stress with combined upregulation of heme oxygenase-1 and ferritin
por: Laporte, Camille, et al.
Publicado: (2019)

Specific Conditions for Resveratrol Neuroprotection against Ethanol-Induced Toxicity
por: Gonthier, Brigitte, et al.
Publicado: (2012)

Stimulatory effect of imeglimin on incretin secretion
por: Yingyue, Quan, et al.
Publicado: (2023)

Effects of the anti-diabetic imeglimin in hyperglycemic mice with septic shock
por: Wagner, F, et al.
Publicado: (2012)

Protection of pancreatic INS-1 β-cells from glucose- and fructose-induced cell death by inhibiting mitochondrial permeability transition with cyclosporin A or metformin
por: Lablanche, S, et al.
Publicado: (2011)

Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects
por: Fouqueray, Pascale, et al.
Publicado: (2022)

Ubiquinone Analogs: A Mitochondrial Permeability Transition Pore-Dependent Pathway to Selective Cell Death
por: Devun, Flavien, et al.
Publicado: (2010)

Glycine Supplementation in Obesity Worsens Glucose Intolerance through Enhanced Liver Gluconeogenesis
por: Alves, Anaïs, et al.
Publicado: (2022)

Imeglimin‐mediated glycemic control in maternally inherited deafness and diabetes
por: Ishibashi, Ryoichi, et al.
Publicado: (2023)

Effects of imeglimin on mitochondrial function, AMPK activity, and gene expression in hepatocytes
por: Hozumi, Kaori, et al.
Publicado: (2023)

Intermittent Hypoxia Rewires the Liver Transcriptome and Fires up Fatty Acids Usage for Mitochondrial Respiration
por: Gaucher, Jonathan, et al.
Publicado: (2022)

Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes
por: Vuylsteke, Valerie, et al.
Publicado: (2015)

Glucose-Lowering Effects of Imeglimin and Its Possible Beneficial Effects on Diabetic Complications
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

Development of Imeglimin Electrospun Nanofibers as a Potential Buccal Antidiabetic Therapeutic Approach
por: Alamer, Ali A., et al.
Publicado: (2023)

Letter to the Editor: Can Imeglimin Improve the Systolic Time Intervals in Diabetes Mellitus?
por: Nishikawa, Tomoaki, et al.
Publicado: (2023)

Improving the Effects of Imeglimin on Endothelial Function: A Prospective, Single-Center, Observational Study
por: Uchida, Taisuke, et al.
Publicado: (2023)

Regulation of Mitochondria-Associated Membranes (MAMs) by NO/sGC/PKG Participates in the Control of Hepatic Insulin Response
por: Bassot, Arthur, et al.
Publicado: (2019)

Cerebral Gluconeogenesis and Diseases
por: Yip, James, et al.
Publicado: (2017)

Gluconeogenesis in the kidney: in health and in chronic kidney disease
por: Dalga, Delal, et al.
Publicado: (2023)

FoxO6 Integrates Insulin Signaling With Gluconeogenesis in the Liver
por: Kim, Dae Hyun, et al.
Publicado: (2011)

Lkb1 suppresses amino acid-driven gluconeogenesis in the liver
por: Just, Pierre-Alexandre, et al.
Publicado: (2020)

Liver or kidney: Who has the oar in the gluconeogenesis boat and when?
por: Sahoo, Biswajit, et al.
Publicado: (2023)

Current understanding of imeglimin action on pancreatic β‐cells: Involvement of mitochondria and endoplasmic reticulum homeostasis
por: Fauzi, Muhammad, et al.
Publicado: (2022)

Potential Ketoacidosis Linked to Imeglimin and Metformin Co-administration in a Patient With Type 2 Diabetes
por: Yamagishi, Hirofumi, et al.
Publicado: (2023)

A Response to Letter to the Editor: Can Imeglimin Improve the Systolic Time Intervals in Diabetes Mellitus?
por: Uchida, Taisuke, et al.
Publicado: (2023)

Lipopolysaccharide inhibits hepatic gluconeogenesis in rats: The role of immune cells
por: Tanaka, Hiroshi, et al.
Publicado: (2017)

A subcutaneous adipose tissue–liver signalling axis controls hepatic gluconeogenesis
por: Reilly, Shannon M., et al.
Publicado: (2015)

Inhibition of Gluconeogenesis by Boldine in the Perfused Liver: Therapeutical Implication for Glycemic Control
por: Silva, Laís Cristina Lima, et al.
Publicado: (2023)

Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study
por: Fouqueray, Pascale, et al.
Publicado: (2021)

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
por: Fouqueray, Pascale, et al.
Publicado: (2013)

A novel mechanism of imeglimin‐mediated insulin secretion via the cADPR‐TRP channel pathway
por: Funazaki, Shunsuke, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9n2mvsrpf64d2nko2o5hn4t7ph